

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 3

Amendments to the claims:

Please cancel claims 1-9 and 11-18 without prejudice to the Applicants' rights to pursue the subject matters in a future application, and add new claims 25-43.

1. (Canceled) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage, wherein the genome of the bacteriophage has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein.
2. (Canceled) The composition according to claim 1 in which the bacterium is a *Salmonella*.
3. (Canceled) The composition according to claim 1 in which the Gram-negative bacterium is *Shigella*.
4. (Canceled) The composition according to claim 1 in which the gene product of interest is a proteinaceous molecule.
5. (Canceled) The composition according to claim 1 in which the gene product of interest is an antigen.
6. (Canceled) The composition according to claim 4 in which the molecule is selected from the group consisting of a

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 4

cytokine, a cytotoxin, a pro-drug converting enzyme and an anti-angiogenic agent.

7. (Canceled) The composition according to claim 6 in which the cytotoxin is a bacteriocin.

8. (Canceled) A kit comprising an attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage, wherein the genome of the bacteriophage has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein, together with instructions for administering the attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage to a subject to deliver the gene product of interest.

9. (Canceled) A kit comprising an attenuated, tumor-targeting Gram-negative bacterium expressing the F' pilus and a filamentous bacteriophage, wherein the genome of the bacteriophage has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein, together with instructions for administering the attenuated, tumor-targeting Gram-negative bacterium expressing the F' pilus and a filamentous bacteriophage to a subject to deliver the gene product of interest.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 5

10. (Canceled)

11. (Canceled) A method for delivering an agent comprising administering, to a subject, a pharmaceutical composition comprising an attenuated Gram-negative bacterium containing a bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode for a gene of interest as a fusion protein with a bacteriophage capsid protein.

12. (Canceled) The method according to claim 11, in which the gene of interest is an antigen or a pro-drug converting enzyme.

13. (Canceled) The method according to claim 11, in which the gene of interest is fused with a bacteriophage capsid protein.

14.. (Canceled) A method for delivering an agent comprising administering, to a subject, a pharmaceutical composition comprising an attenuated Gram-negative bacterium expressing the F' pilus and a filamentous bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode for a gene of interest as a fusion protein with a bacteriophage capsid protein.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 6

15. (Canceled) A method of inhibiting tumor growth or reducing tumor volume comprising administering, to a subject in need of such inhibition or reduction, a pharmaceutical composition comprising an attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein.

16. (Canceled) The method according to claim 15 in which the Gram-negative bacterium is *Salmonella* or *Shigella*.

17. (Canceled) A method of inhibiting tumor growth or reducing tumor volume comprising administering, to a subject in need of such inhibition or reduction, a pharmaceutical composition comprising an attenuated, tumor-targeting Gram-negative bacterium expressing the F' pilus and a bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein.

18. (Canceled) The method according to claim 17 in which the Gram-negative bacterium is *Salmonella* or *Shigella*.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 7

19.-24. (Cancelled)

Please add the following new claims 25-43, as follows:

25. A *Salmonella* strain which expresses F' pilus and produces filamentous bacteriophage and is capable of targeting tumors by intravenous administration.

26. A *Salmonella* strain which expresses F' pilus and produces filamentous bacteriophage and is capable of targeting tumors by intravenous administration and producing phage directly within tumors.

27. (New) The *Salmonella* according to Claim 25, wherein the *Salmonella* is attenuated.

28. (New) The *Salmonella* according to Claim 26, wherein the *Salmonella* is attenuated.

29. (New) A composition comprising the *Salmonella* of claim 25.

30. (New) A composition comprising the *Salmonella* of claim 26.

31. (New) The composition according to Claim 29, wherein the *Salmonella* is attenuated.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 8

32. (New) The composition according to Claim 30, wherein the Salmonella is attenuated.

33. (New) The composition according to Claim 31 in which the Salmonella strain is attenuated by an msbB- mutation.

34. (New) The composition according to Claim 31 in which the Salmonella is attenuated by a pur- mutation.

35. (New) The composition according to Claim 32 in which the Salmonella strain is attenuated by an msbB- mutation.

36. (New) The composition according to Claim 32 in which the Salmonella is attenuated by a pur- mutation.

37. (New) A method for delivering filamentous bacteriophage to solid tumors by intravenous administration of attenuated tumor-targeted Salmonella engineered to contain a filamentous bacteriophage of interest.

38. (New) A kit comprising an attenuated, tumor-targeting Salmonella expressing F' pilus suitable for delivery of a filamentous bacteriophage cloning vector to tumors by intravenous administration.

39. (New) A kit according to claim 38 in which the filamentous bacteriophage cloning vector possesses a eukaryotic promoter.

Applicants : BERMUDES, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 9

40. (New) The Salmonella according to claim 25, wherein the Salmonella is capable of delivering between 2.7×10^9 p.f.u. (plaque forming unit)/gram and 4.6×10^{11} p.f.u./gram of phage to tumors.

41. (New) The Salmonella according to claim 26, wherein the Salmonella is capable of delivering between 2.7×10^9 gram p.f.u./gram and 4.6×10^{11} p.f.u./gram of phage to tumors.

42. (New) The Salmonella according to claim 27, wherein the Salmonella is capable of delivering between 2.7×10^9 p.f.u./gram and 5.9×10^9 p.f.u./gram of phage to tumors.

43. (New) The Salmonella according to claim 28, wherein the Salmonella is capable of delivering between 2.7×10^9 p.f.u./gram and 5.9×10^9 p.f.u./gram of phage to tumors.